IDiyas

For the Inventor, By the Inventor

Wuppertal, Germany

Rolf Angerbauer

USPTO Granted Patents = 50

Average Co-Inventor Count = 5.2

ph-index = 12

Forward Citations = 623(Granted Patents)

Forward Citations (Not Self Cited) = 579(Oct 12, 2025)


Inventors with similar research interests:


Location History:

  • Kobe, JP (1998 - 2000)
  • Kobe, DE (2000)
  • Wuppertal, DE (1986 - 2001)

Company Filing History:

goldMedal50 out of 12,157 
 
Bayer Aktiengesellschaft
 patents

Years Active: 1986-2001

Loading Chart...
50 patents (USPTO):Explore Patents
1. 6277833 - Substituted triols (2001-08-21),
2. 6207671 - Cycloalkano-pyridines (2001-03-27),
3. 6127383 - 2-aryl-substituted pyridines (2000-10-03),
4. 6121330 - 5-Hydroxyalkyl substituted phenyls and their use in medicaments for the (2000-09-19),
5. 6069148 - Cycloalkano-pyridines (2000-05-30),
6. 6063788 - Bicyclic-fused pyridines (2000-05-16),
7. 5932587 - Heterocyclic-fused pyridines (1999-08-03),
8. 5925645 - 2-aryl-substituted pyridines (1999-07-20),
9. 5861385 - Substituted triols (1999-01-19),
10. 5849749 - 6-(hydroxymethyl-ethyl)pyridines (1998-12-15),
11. 5693650 - 4-(Quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives (1997-12-02),
12. 5502199 - Process for preparing sodium (1996-03-26),
13. 5502057 - Polysubstituted pyridines useful for treating lipoproteinanaemia and (1996-03-26),
14. 5470982 - Disubstituted pyridines (1995-11-28),
15. 5418243 - Substituted 4-phenyl-pyridones and 4-phenyl-3-alkoxypyridines (1995-05-23),

Title: Rolf Angerbauer: Innovator in Medicinal Chemistry

Introduction: Rolf Angerbauer is a distinguished inventor based in Wuppertal, Germany, renowned for his significant contributions to medicinal chemistry. With an impressive portfolio of 50 patents, Angerbauer's work focuses on developing innovative active substances for use in medications.

Latest Patents: Among his latest patents, Angerbauer has made remarkable strides in the preparation of substituted triols. These compounds are synthesized by reducing appropriately substituted carboxylic esters and are valuable as active substances in medicaments. Additionally, he has developed cycloalkano-pyridines through reactions involving cycloalkano-pyridine-aldehydes and suitable organometallic compounds. These cycloalkanopyridines are particularly promising as active compounds for treating hyperlipoproteinemia and arteriosclerosis.

Career Highlights: Rolf Angerbauer's career is marked by his association with Bayer Aktiengesellschaft, a leading global pharmaceutical and life sciences company. His innovative research and development efforts have played a critical role in advancing the company's portfolio of medicinal products.

Collaborations: Throughout his career, Angerbauer has collaborated with esteemed colleagues such as Hilmar Bischoff and Delf Schmidt. Their joint efforts have facilitated the exploration of new pharmaceutical avenues and the enhancement of drug formulations.

Conclusion: Rolf Angerbauer's commitment to innovation in the field of medicinal chemistry is reflected in his extensive patent portfolio and collaborative projects. His work continues to have a positive impact on the development of effective treatments for various medical conditions, reinforcing his status as a key inventor in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…